In DCE-MRI, advanced pharmacokinetic models, such as the 2CX, TH and ATH models, provide a more complete set of pharmacokinetic parameters than the commonly used simpler models, such as the Tofts and Patlak models. However, their use requires higher temporal resolution and signal-to-noise ratio. Hence, advanced-model DCE-MRI allows for imaging of only a few slices. We present an approach making 3D advanced-model DCE-MRI possible and evaluate it under the low-signal-to-noise-ratio conditions of small-animal MRI. Our methodology is based on compressed sensing and spatially regularized fitting of the pharmacokinetic model. The approach is evaluated on simulated and real datasets.
No takes yet. Share an insight, caveat, or question.
Jiřík et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: